Drug Profile
Research programme: KMO inhibitors - Kynos Therapeutics
Alternative Names: KMO inhibitors - GlaxoSmithKline/University of Edinburgh; Kynurenine 3-monooxygenase inhibitors - Kynos TherapeuticsLatest Information Update: 20 Apr 2022
Price :
$50
*
At a glance
- Originator GlaxoSmithKline; University of Edinburgh
- Developer Kynos Therapeutics
- Class Anti-inflammatories; Benzoxazoles; Chlorine compounds; Oxazolidinones
- Mechanism of Action Kynurenine 3-monooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Metabolic disorders; Pancreatitis